DEFIBROTIDE
(Defitelio)Standard Prescription
Defibrotide __ mg IV Q6H (__ mg/kg/dose)
Dosages
Treatment of sinusoidal obstruction syndrome (SOS) aka veno-occlusive disease (VOD)
Children and adults
6.25 mg/kg/dose IV Q6H
(use baseline weight prior to preparative conditioning regimen)
Children and adults
6.25 mg/kg/dose IV Q6H
(use baseline weight prior to preparative conditioning regimen)
Mechanism of Action
Defibrotide protects the endothelium lining blood vessels from damage by fludarabine, a chemotherapy drug, and from other insults like serum starvation. It also appears to increase t-PA function and decrease plasminogen activator inhibitor-1 activity.
Forms Supplied
Injection: 80 mg/mL (2.5 mL)
Comments
Possible adverse effects: hypotension, bleeding, nausea, vomiting.
Do not give concomitantly with anti-coagulants (with the exception of heparin-locks).
Do not use in patients with active and/or clinically significant bleeding.
Discontinue 2 hours prior to invasive procedures; may resume when risk of bleeding is resolved.
There is no known reversal agent for defibrotide.
Do not give concomitantly with anti-coagulants (with the exception of heparin-locks).
Do not use in patients with active and/or clinically significant bleeding.
Discontinue 2 hours prior to invasive procedures; may resume when risk of bleeding is resolved.
There is no known reversal agent for defibrotide.
References
44, 465, 467
Last Edited
2021-11-12 07:51:16